2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. FGFR

FGFR

Fibroblast growth factor receptor

FGFR

Related Products

PDF 1.46 MB

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100315
    XL 999
    		Inhibitor 99.01%
    XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC50 values for KDR, Flt-1, FGFR1 and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer.
    XL 999
  • HY-13302B
    CP-547632 hydrochloride
    		Inhibitor 99.79%
    CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy.
    CP-547632 hydrochloride
  • HY-141600
    Aprutumab ixadotin
    		Inhibitor 98.99%
    Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer.
    Aprutumab ixadotin
  • HY-W001179R
    2,5-Dihydroxybenzoic acid (Standard)
    		Inhibitor
    2,5-Dihydroxybenzoic acid (Standard) is the analytical standard of 2,5-Dihydroxybenzoic acid. This product is intended for research and analytical applications. 2,5-Dihydroxybenzoic acid is a derivative of benzoic and a powerful inhibitor of fibroblast growth factors.
    2,5-Dihydroxybenzoic acid (Standard)
  • HY-145230
    FGFR2-IN-1
    		Inhibitor 99.78%
    FGFR2-IN-1 is a selective FGFR2 inhibitor with an IC50 of 140 nM.
    FGFR2-IN-1
  • HY-N0183R
    Formononetin (Standard)
    		Inhibitor
    Formononetin (Standard) is the analytical standard of Formononetin. This product is intended for research and analytical applications. Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth.
    Formononetin (Standard)
  • HY-16025
    EOC317
    		Inhibitor 98.01%
    EOC317 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2.
    EOC317
  • HY-W006833
    1-Phenylindole
    		99.78%
    1-Phenylindole (Compound 8) is a 1-Phenylbenzimidazole analogue. 1-Phenylindole shows IC50 values of >50 μM and >50 μM for PDGFR and FGFR, respectively. 1-Phenylbenzimidazole is a selective PDGFR inhibitor.
    1-Phenylindole
  • HY-18603
    FIIN-3
    		Inhibitor 99.01%
    FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
    FIIN-3
  • HY-100631
    FGFR4-IN-1
    		Inhibitor 99.43%
    FGFR4-IN-1 (example 98) is a potent inhibitor of FGFR4 with IC50 of 0.4 nM.
    FGFR4-IN-1
  • HY-131908
    CPL304110
    		Inhibitor 99.85%
    CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), with IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively.
    CPL304110
  • HY-156672
    S6K2-IN-1
    		Inhibitor 98.75%
    S6K2-IN-1 (Compound 2) is a S6K2 inhibitor (IC50: 22 nM). S6K2-IN-1 also inhibits FGFR4 (IC50: 216 nM). S6K2-IN-1 has acceptable stability in mouse liver microsomes.
    S6K2-IN-1
  • HY-50904S2
    Nintedanib-d8
    		Inhibitor 99.90%
    Nintedanib-d8 is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib-d<sub>8</sub>
  • HY-163705
    BR-cpd7
    		Degrader 98.01%
    BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor FGFR1/2 with DC50 of 10 nM. BR-cpd7 arrests cell cycle, inhibits proliferations of FGFR1/2 aberrant activated tumor cells. (Pink: ligand for target protein FGFR-IN-12 (HY-160013); Black: linker; Blue: ligand for E3 ligase Thalidomide-NH-CH2-COOH (HY-131717))
    BR-cpd7
  • HY-10987
    ENMD-2076 Tartrate
    		Inhibitor 99.66%
    ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
    ENMD-2076 Tartrate
  • HY-10981R
    Lenvatinib (Standard)
    		Inhibitor
    Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
    Lenvatinib (Standard)
  • HY-175743
    TYRA-200
    		Inhibitor 98.06%
    TYRA-200 is a potent and orally active FGFR2 inhibitor. TYRA-200 inhibits the kinase activity of wild-type FGFR2 and its mutants. TYRA-200 induces significant tumor regression in FGFR2-driven cancer models. TYRA-200 can be used for the research of FGFR2-altered advanced solid tumors, intrahepatic cholangiocarcinoma, and endometrial cancer.
    TYRA-200
  • HY-145895
    SNIPER(TACC3)-11
    		Inhibitor 99.58%
    SNIPER(TACC3)-11 is a potent FGFR3-TACC3 degrader. SNIPER(TACC3)-11 reduces FGFR3-TACC3 protein levels and suppressed the growth of FGFR3-TACC3 positive cancer cells.
    SNIPER(TACC3)-11
  • HY-15599
    SSR128129E
    		Inhibitor 99.18%
    SSR128129E is an orally available and allosteric FGFR inhibitor with an IC50 of 1.9 μM for FGFR1.
    SSR128129E
  • HY-10981S
    Lenvatinib-d4
    		Inhibitor 99.59%
    Lenvatinib-d4 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
    Lenvatinib-d<sub>4</sub>
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity